As more drugs lose their patents, generic competition is becoming a more dominant force.

Direct-to-consumer pharmaceutical advertising has long been controversial. New research suggests it may also be ineffective.

Companies have fought to release generic versions of drugs, which has yielded mixed results.

The companies will launch generic versions of Ortho-McNeil's drug Razadyne.

The biopharma's shares tanked on bad news from its prostate cancer drug, but earlier data could turn that around.